Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Xtalks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Xtalks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Advancing Neurotherapeutics for Fragile X and Beyond with Spinogenix CMO Dr. Craig Erickson

37:11
 
Share
 

Manage episode 500006358 series 2900042
Content provided by Xtalks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Xtalks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Craig Erickson, MD, chief medical officer at Spinogenix and a leading expert in translational neurodevelopmental research.

Dr. Erickson shares insights into Spinogenix’s work on restoring synapses to reverse cognitive and motor decline in conditions like Fragile X Syndrome, ALS, Alzheimer’s disease and schizophrenia.

Dr. Erickson is a Professor of Psychiatry at the University of Cincinnati College of Medicine-Affiliated and the Director of the Cincinnati Fragile X Research and Treatment Center. His work focuses on enhancing the ability to detect brain target engagement with treatment to identify meaningful functional changes in patients as early as the initial stages of human drug trials, while also determining which individuals are most likely to benefit from treatment.

Dr. Erickson holds several investigator-initiated INDs and is the inventor of several patents describing new treatment approaches. His work has been extensively supported by the NIH, CDC, US Department of Defense, stakeholder foundations and biotechnology companies from around the world.

Tune into the episode to hear Dr. Erickson discuss the evolving landscape of neurotherapeutics, early-stage drug trials and how precision biomarkers are shaping individualized treatment approaches.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  continue reading

225 episodes

Artwork
iconShare
 
Manage episode 500006358 series 2900042
Content provided by Xtalks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Xtalks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Craig Erickson, MD, chief medical officer at Spinogenix and a leading expert in translational neurodevelopmental research.

Dr. Erickson shares insights into Spinogenix’s work on restoring synapses to reverse cognitive and motor decline in conditions like Fragile X Syndrome, ALS, Alzheimer’s disease and schizophrenia.

Dr. Erickson is a Professor of Psychiatry at the University of Cincinnati College of Medicine-Affiliated and the Director of the Cincinnati Fragile X Research and Treatment Center. His work focuses on enhancing the ability to detect brain target engagement with treatment to identify meaningful functional changes in patients as early as the initial stages of human drug trials, while also determining which individuals are most likely to benefit from treatment.

Dr. Erickson holds several investigator-initiated INDs and is the inventor of several patents describing new treatment approaches. His work has been extensively supported by the NIH, CDC, US Department of Defense, stakeholder foundations and biotechnology companies from around the world.

Tune into the episode to hear Dr. Erickson discuss the evolving landscape of neurotherapeutics, early-stage drug trials and how precision biomarkers are shaping individualized treatment approaches.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  continue reading

225 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play